Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Harbeck

Showing results (71-80 of 585) with videos related to

Pageof 59
Sort By:
Breast Care (Basel, Switzerland)|December 5, 2019
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer TreatmentMarija Balic, Christoph Thomssen, Rachel Würstlein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2025
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et alOleg Gluz, Ronald Kates, Sherko Kuemmel, et al.
Breast Cancer Research and Treatment|October 21, 2010
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patientsMathias Warm, Ronald Kates, Friedrich Overkamp, et al.
Drugs in R&D|September 8, 2017
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell LinesXi Zhang, Simone Hofmann, Nadia Harbeck, et al.
Breast Care (Basel, Switzerland)|September 9, 2010
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerHiltrud Brauch, Werner Schroth, Michel Eichelbaum, et al.
Breast Care (Basel, Switzerland)|March 16, 2012
Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current LiteratureIngo Gottschalk, Christoph Berg, Nadia Harbeck, et al.
Onkologie|October 27, 2010
Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstructionVolker R Jacobs, Linda Rasche, Nadia Harbeck, et al.
Methods in Molecular Medicine|February 24, 2006
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISAManfred Schmitt, Alexandra S Sturmheit, Anita Welk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancerMatthias Christgen, Nadia Harbeck, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?Paolo Tarantino, Sara M Tolaney, Nadia Harbeck, et al.
Pageof 59

Showing results (71-80 of 585) with videos related to

Sort By:
Pageof 59
Breast Care (Basel, Switzerland)|December 5, 2019
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer TreatmentMarija Balic, Christoph Thomssen, Rachel Würstlein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2025
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et alOleg Gluz, Ronald Kates, Sherko Kuemmel, et al.
Breast Cancer Research and Treatment|October 21, 2010
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patientsMathias Warm, Ronald Kates, Friedrich Overkamp, et al.
Drugs in R&D|September 8, 2017
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell LinesXi Zhang, Simone Hofmann, Nadia Harbeck, et al.
Breast Care (Basel, Switzerland)|September 9, 2010
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerHiltrud Brauch, Werner Schroth, Michel Eichelbaum, et al.
Breast Care (Basel, Switzerland)|March 16, 2012
Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current LiteratureIngo Gottschalk, Christoph Berg, Nadia Harbeck, et al.
Onkologie|October 27, 2010
Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstructionVolker R Jacobs, Linda Rasche, Nadia Harbeck, et al.
Methods in Molecular Medicine|February 24, 2006
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISAManfred Schmitt, Alexandra S Sturmheit, Anita Welk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancerMatthias Christgen, Nadia Harbeck, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?Paolo Tarantino, Sara M Tolaney, Nadia Harbeck, et al.
Pageof 59